Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jennifer Erdman

Nurse Practitioner, Psychiatric/Mental Health Rapid City, SD Nurse Practitioner

NPI 1013222157 CMS profile 10453026

636 Saint Anne St, Rapid City, SD 57701

Open in the dashboard

General payments

$5,700

284 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Erdman of Rapid City, SD is reported in the CMS Open Payments database as having received $5,700 across 284 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,547 81
2024 General $1,347 58
2023 General $1,108 56
2022 General $1,151 57
2021 General $548 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Erdman
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Jennifer Erdman were reported at $1,547. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Jennifer Erdman Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $548 $166 $54–$482 $132
2022 $1,151 $195 $66–$559 $149
2023 $1,108 $233 $82–$673 $160
2024 $1,347 $236 $84–$688 $164
2025 $1,547 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,319 78 payments
  2. ITI, Inc. $795 38 payments
  3. Alkermes, Inc. $622 30 payments
  4. Harmony Biosciences LLC $566 26 payments
  5. Axsome Therapeutics, Inc. $398 13 payments
  6. Lundbeck LLC $317 16 payments
  7. Teva Pharmaceuticals USA, Inc. $264 13 payments
  8. Supernus Pharmaceuticals, Inc. $254 15 payments
  9. Vanda Pharmaceuticals Inc. $231 6 payments
  10. Otsuka America Pharmaceutical, Inc. $206 12 payments
  11. Other $727 37 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,634 280 payments
  2. Education $66 4 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $1,042 51 payments
  2. LYBALVI Cns $593 28 payments
  3. CAPLYTA $579 29 payments
  4. LYBALVI Cns $463 20 payments
  5. Auvelity $398 13 payments
  6. LYBALVI Cns $358 13 payments
  7. LYBALVI Cns $358 13 payments
  8. REXULTI $317 16 payments
  9. VRAYLAR Neuroscience $278 27 payments
  10. ARISTADA $265 17 payments
  11. Other $3,183 164 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

442

Median for Nurse Practitioner: 389

Drug cost

$30,521

Median for Nurse Practitioner: $21,885

Branded share of claims

20.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 14 $22,636
Vilazodone Hcl Generic 35 $3,474
Duloxetine Hcl Generic 55 $698
Bupropion Xl Bupropion Hcl Brand 21 $503
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 13 $450
Trazodone Hcl Generic 44 $419
Lorazepam Generic 70 $352
Aripiprazole Generic 19 $311
Quetiapine Fumarate Generic 24 $286
Olanzapine Odt Olanzapine Brand 16 $226

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $275
$275 14 —
WAKIX
  • Harmony Biosciences LLC $239
$239 — —
CAPLYTA
  • ITI, Inc. $207
$207 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $184
$184 — —
REXULTI
  • Lundbeck LLC $101
$101 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

284 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in South Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record